Abstract 226P
Background
Urothelial carcinoma (UC) has a highly complex genomic landscape. With the spread of immunotherapy, accurate stratification strategies are needed. As cancer tissues are now frequently screened for specific sets of mutations, a large number of samples has become available for analysis. Classification of patients with similar mutation profiles may help identifying subgroups of patients outcomes. However, classification based on somatic mutations is challenging due to the sparseness and heterogeneity of the data.
Methods
A retrospective study was performed to identify the prognosis-related somatic mutations from 192 UC in The Cancer Genome Atlas (TCGA) database. Cox regression were performed to screen out prognostic genes.
Results
A total of 176 genes were related with immuno-survival. Then, a stepwise multivariate Cox regression analysis was performed, and 14 gene were selected to establish a predictive model. Compared with the wildtype group, the patients with mutated signature had unfavorable to prognosis (p<0.001). ROC curve analysis demonstrated the predictive ability for 1-, 3-, 5-, and 10-year OS, with areas under the curve (AUCs) of 0.7684, 0.667,0.619 and 0.647, respectively. In mutated signature cohorts, the five most frequently mutated genes were TP53 (50%), KMT2D (43%), LRP1B (33%), PER1 (33%), and RNF213 (33%). Dissimilarly, the five most frequently mutated genes were TP53 58%), ARID1A (29%), KMT2D (29%), RNF213 (27%), and KDM6A (26%) in wildtype cohorts, which may imply that different characteristic states have different molecular mechanisms.
Conclusions
These data underline the potential value of using somatic mutations to accurately stratify UC patients into clinically actionable subgroups. This model could reduce overtreatment in UC patients with mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract